In recent years, electric field therapy for tumors has gradually become familiar to everyone. Clinical trials abroad have shown that electric field therapy is effective for several types of cancer, including glioma. So I will now briefly introduce the knowledge about electric field therapy. The electric field therapy system for glioma is a portable device that generates a medium frequency low field strength tumor treatment magnetic field through a conversion sheet applied to the scalp. Current studies have shown that electric field therapy is safe and effective, and is recommended for the treatment of new glioblastoma and recurrent high-grade glioma. TTFields have been approved for the treatment of newly diagnosed and recurrent glioblastoma in 2016 and 2011 in the US, EU, and Japan. In phase III clinical trials, the combination of TTF and adjuvant TMZ after standard concurrent radiotherapy treatment for newly diagnosed GBM could significantly improve patient progression-free survival by 2.7 months and overall survival by 4.9 months over TMZ chemotherapy alone, without increasing the side effects of the combination therapy. TTFields are a new treatment modality that has emerged in recent years to prolong survival in patients with glioblastoma and has been approved by the FDA, and combined with TMZ for GBM, worn for more than 22 hours per day, has resulted in a five-year survival rate of 30%. According to the 2018 NCCN guidelines and the 2018 China Health Care Commission’s “Glioma Diagnosis and Treatment Standards” recommendations, the new standard of care for newly diagnosed glioblastoma is “surgery + simultaneous radiotherapy + adjuvant temozolomide chemotherapy + TTFields”. TTFields power plant treatment is less toxic and less damaging to the human body than traditional treatment methods, and is easily accepted by patients, and can also have a sensitizing effect on chemotherapy.